Auron Therapeutics, Inc.
Last verified 2026-05-05. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $13.4Mattributed |
|---|---|
| Latest round | Funding round, $13.4M, 2024-12-18attributed |
| Founded | unknown |
| Headquarters | Newton, MA |
| Industry | bio |
| Stage | unknown |
| Website | aurontx.com |
AI-driven AURIGIN drug-discovery platform with a lead candidate, AUTX-703, targeting cell-state plasticity. Develops therapies for AML, small-cell lung cancer, and neuroendocrine prostate cancer. Combines machine learning with biological insight to design small molecules in oncology and inflammation.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-12-18 | Funding round | $13.4M | undisclosed |
Detected tech stack
Cloudflare, Google Font API, Google Hosted Libraries, Google Tag Manager, jquery 3.5.1
Provenance
| Fact | Status | Basis |
|---|---|---|
| Funding round, $13.4M | attributed | sec-edgar named as publisher. No document URL on file. |
| Total raised $13.4M | attributed | sec-edgar named as publisher. No document URL on file. |
| Company existence | self-reported | aurontx.com, read 2026-05-05 |
| Description | self-reported | aurontx.com, read 2026-05-05 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-25Latest round: seed, $13.4M, 2024-12-18 → Funding round, $13.4M, 2024-12-18, sec-edgar, No document URL on file | Latest round | seed, $13.4M, 2024-12-18 → Funding round, $13.4M, 2024-12-18 | sec-edgar, No document URL on file |
Records begin 2026-09-24. All changes